ACM
RDHL

ACT Capital Management’s Redhill Biopharma RDHL Stock Holding History

ACT Capital Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-140
Closed -$964K – 127
2021
Q2 		$964K Buy
+140
New +$966K 0.5% 42

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ACT Capital Management's RDHL Position: Q3 2021 in Review

ACT Capital Management sold out of Redhill Biopharma (RDHL) in Q3 2021, closing a stake of 140 shares — an estimated $964K sold.

ACT Capital Management first reported a position in RDHL in Q2 2021 and held it in 1 quarter. The position peaked at $964K in Q2 2021. 53 funds tracked by Wall St. Rank hold RDHL as of Q3 2021.

  • ACT Capital Management reported no remaining Redhill Biopharma position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 140 Redhill Biopharma shares in Q3 2021, an estimated $964K.
  • ACT Capital Management first reported a position in Redhill Biopharma in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Redhill Biopharma position peaked at $964K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.